Program
ferric carboxymaltose
Also written as “Ferric Carboxymaltose (FCM)”, “Ferric carboxymaltose” and “Injectafer”.
Its studies are mostly in Anemia, Iron-Deficiency · Anemia · Iron Deficiencies · Restless Legs Syndrome · Heart Failure, led by 4 companies.
Drug pageFerric carboxymaltose: every studyAll 158 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Daiichi Sankyoits history only | 280 open or running | phase 4since Sep 23, 2013 | Apr 20, 2006 | none ahead |
| CSL | 140 open or running | phase 4since Mar 29, 2010 | Aug 24, 2007 | none ahead |
| Sichuan Huiyu Pharmaceuticalits history only | 31 open or running | phase 1since Sep 27, 2023 | Sep 27, 2023 | none ahead |
| Novartisits history only | 10 open or running | phase 1since Dec 5, 2017 | Dec 5, 2017 | none ahead |
Also a collaborator on its studies: Suzhou Guochen Biotechnology, Boji Medical Technology, ClinStar, Cytel, Tigermed Consulting, Pierrel Research Europe, ICON Clinical Research, Parexel and SGS.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of CSL only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 24, 2007First study: phase 3 study in Iron DeficienciesFirst studyNCT00520780 · 456 enrolled · Argentina, Germany, Greece and more
- Dec 16, 20082 phase 3 studiesNCT00810030, NCT00810004
- Jan 7, 2009Phase 3 study in Iron DeficienciesNCT00821717 · 35 enrolled · Denmark, France, Germany and more
- Apr 15, 2009Phase 2 study in ThrombocytosisNCT00882414 · 26 enrolled · Austria
- Oct 12, 2009Phase 3 study in Anemia, Iron-DeficiencyNCT00994318 · 626 enrolled · United States, Australia, Austria and more
- Mar 29, 2010Phase 4 study in Anemia, Iron-DeficiencyNCT01100879 · 3 enrolled · France, Greece
- Mar 30, 2010Phase 3 study in Anemia, Iron-DeficiencyNCT01101399 · 19 enrolled · Germany, Sweden
- Apr 22, 2010Phase 4 study in Iron DeficienciesNCT01110356 · 294 enrolled · Austria
- May 25, 2010Phase 3 study in AnemiaNCT01131624 · 252 enrolled · Australia, Germany, Sweden and more
- Jul 12, 2011Phase 3 study in Iron DeficienciesNCT01394562 · 174 enrolled · Netherlands
- Oct 13, 2011Phase 4 study in Iron DeficienciesNCT01453608 · 304 enrolled · Poland, Russian Federation
- Oct 14, 2016Phase 4 study in Iron DeficienciesNCT02937454 · 1,132 enrolled · Argentina, Brazil, Croatia and more
- Jun 22, 2018Phase 3 study in Anemia, Iron-DeficiencyNCT03591406 · 371 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 14 CSL leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03591406Anemia, Iron-Deficiency · China | 3 | Completed | Feb 25, 2019 | 371 |
| NCT02937454Iron Deficiencies · Argentina, Brazil, Croatia and more | 4 | Completed | Jul 21, 2020 | 1,132 |
| NCT01453608Iron Deficiencies · Poland, Russian Federation | 4 | Completed | Feb 2014 | 304 |
| NCT01394562Iron Deficiencies · Netherlands | 3 | Completed | May 2016 | 174 |
| NCT01131624Anemia · Australia, Germany, Sweden and more | 3 | Completed | May 2014 | 252 |
| NCT01110356Iron Deficiencies · Austria | 4 | Completed | Oct 2011 | 294 |
| NCT01101399Anemia, Iron-Deficiency · Germany, Sweden | 3 | Completed | Nov 2012 | 19 |
| NCT01100879Anemia, Iron-Deficiency · France, Greece | 4 | Terminated | Jul 2011 | 3 |
| NCT00994318Anemia, Iron-Deficiency · United States, Australia, Austria and more | 3 | Completed | Feb 2013 | 626 |
| NCT00882414Thrombocytosis · Austria | 2 | Terminated | Jan 2010 | 26 |
| NCT00821717Iron Deficiencies · Denmark, France, Germany and more | 3 | Terminated | Oct 2009 | 35 |
| NCT00810030Inflammatory Bowel Diseases · Austria | 3 | Completed | Dec 2009 | 484 |
| NCT00810004Iron Deficiencies · Russian Federation | 3 | Completed | Oct 2010 | 245 |
| NCT00520780Iron Deficiencies · Argentina, Germany, Greece and more | 3 | Completed | Jul 2009 | 456 |
How it is read
Names in the registry
- “Ferric Carboxymaltose (FCM)”, 13 entries
- “Ferric carboxymaltose”, 8 entries
- “Injectafer”, 5 entries
- “Ferric Carboxymaltose”, 5 entries
- “Ferric Carboxymaltose Injection”, 3 entries
Conditions, from the studies’ own filings
- Anemia, Iron-Deficiency, 17 studies
- Anemia, 12 studies
- Iron Deficiencies, 7 studies
- Restless Legs Syndrome, 4 studies
- Heart Failure, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.